EMT is a fundamental developmental program that is hijacked in cancer. During EMT, cells lose the apical-basal polarity and cell-cell adhesion molecules, such as E-cadherin, that hold epithelial sheets together, and they instead express mesenchymal markers including N-cadherin, vimentin, and transcriptional repressors of the Snail, Slug, Twist, and Zeb families. In lung biology, this program is deeply implicated in both pathological fibrosis and carcinoma progression, since the same signaling cascades that mobilize epithelial plasticity during wound repair can be co-opted by tumor cells to detach, migrate, invade surrounding tissue, and ultimately seed metastases. Transforming growth factor beta, or TGF-β, is the most potent and widely studied inducer of EMT, activating downstream SMAD-dependent transcription as well as non-canonical pathways involving MAPK, PI3K-AKT, and Rho GTPases.

What has become increasingly clear over the past decade is that EMT is not merely a change in gene expression; it is a wholesale reorganization of cellular metabolism. Epithelial cells, which rely heavily on mitochondrial oxidative phosphorylation to generate ATP, must rewire their energetic machinery to support the demanding biosynthetic needs of a migrating, proliferating cell. Aerobic glycolysis provides rapid ATP and, critically, diverts glycolytic intermediates into branching anabolic pathways, including the pentose phosphate pathway for nucleotide synthesis and serine biosynthesis routes for lipid and amino acid generation. This metabolic flexibility is thought to be a prerequisite for successful EMT rather than simply a byproduct of it, and teasing apart cause from consequence is precisely the challenge that the new work addresses.

The research team focused on lung epithelial cells because the lung represents a clinical arena in which EMT-linked processes carry enormous weight. Idiopathic pulmonary fibrosis involves fibroblast activation and epithelial cell state transitions driven in part by TGF-β, while lung cancers, including non-small cell lung carcinoma, frequently display hybrid epithelial-mesenchymal phenotypes associated with drug resistance and metastatic spread. Understanding whether glycolytic reprogramming is a driver or a passenger in the TGF-β-induced transition of lung epithelial cells therefore has implications that extend from basic cell biology to therapeutic strategy, because metabolic enzymes are, in principle, druggable targets in a way that master transcription factors often are not.

Technically, the investigation combined TGF-β stimulation of lung epithelial cell models with measurements of glycolytic flux, lactate production, and the expression of key glycolytic enzymes such as hexokinase 2, phosphofructokinase, and lactate dehydrogenase A. These functional readouts were integrated with assessments of EMT marker expression, including the loss of E-cadherin and the gain of vimentin and N-cadherin, to establish a temporal and causal relationship between metabolic shift and phenotypic conversion. Such paired metabolic and molecular phenotyping is essential because TGF-β is known to alter numerous cellular processes simultaneously, and only carefully timed interventions can reveal which changes are required for EMT to proceed and which are secondary consequences of it.

The broader literature supports the plausibility of a causal link. Hypoxia-inducible factor 1 alpha, a master regulator of glycolytic gene expression, is stabilized not only by low oxygen but also by TGF-β signaling through mechanisms involving reactive oxygen species and mTOR pathway activation. At the same time, TGF-β suppresses the expression of PPAR gamma coactivator 1 alpha, a key driver of mitochondrial biogenesis, thereby tilting the balance away from oxidative metabolism. Glycolytic enzymes themselves have been reported to moonlight as transcriptional co-regulators; for example, certain glycolysis-associated factors can influence the activity of EMT transcription factors, creating feedback loops in which metabolism and gene expression reinforce one another. If such loops operate in lung epithelial cells, blocking glycolysis could potentially arrest or reverse the EMT program rather than merely slowing cellular energy production.

Therapeutically, the implications are considerable. Drugs that target glycolysis, ranging from hexokinase inhibitors to lactate dehydrogenase inhibitors, have been explored in preclinical cancer models for years, although clinical translation has been complicated by the dependence of normal tissues, including the brain and red blood cells, on glucose metabolism. The value of the new work lies in narrowing the therapeutic window: if glycolytic dependency is specifically induced during the EMT transition in lung epithelial cells, then transient metabolic intervention could be timed to coincide with windows of tumor plasticity, such as during the emergence of resistance to targeted therapies or immune checkpoint inhibitors, when EMT-associated states are thought to be most prominent.

The study also speaks to a conceptual shift in how the field understands cell state transitions. EMT is now recognized not as a binary switch but as a spectrum of hybrid states, with cells occupying partial epithelial-mesenchymal phenotypes that may be particularly aggressive and drug tolerant. Metabolic profiling adds an additional axis to this landscape: hybrid cells may display intermediate glycolytic dependency, fully mesenchymal cells may be the most glycolytic, and reversibility of the process may depend on whether the metabolic reprogramming has been consolidated through epigenetic modification. Stable chromatin changes at EMT gene loci could lock in a mesenchymal state even after the original TGF-β signal dissipates, suggesting that metabolic interventions would need to occur early in the transition to be effective.

For patients with lung disease, the distance between mechanistic cell biology and clinical benefit remains substantial, and the authors’ findings should be understood as foundational rather than immediately actionable. Nevertheless, the convergence of TGF-β biology, metabolic reprogramming, and epithelial plasticity in lung cells offers a coherent framework for developing biomarkers that identify patients whose tumors or fibrotic lesions are undergoing active EMT, and for designing combination regimens in which metabolic inhibitors sensitize cells to existing TGF-β pathway antagonists, kinase inhibitors, or antifibrotic agents. As the field continues to map the metabolic architecture of cell state transitions, studies like this one bring the goal of intervening in cancer progression and fibrosis at the level of cellular identity, rather than merely cellular proliferation, steadily closer to realization.

Subject of Research: The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells

Article Title: The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells

Article References: Huang, S.-W., Chen, H.-C., Peng, S.-Y., Chuang, C.-H., Chen, B.-C., Cheng, W.-H., Cools, J. M. T., Neoh, M.-M., Hsiao, S.-H., & Hsu, M.-J. (2026). The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03322-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03322-5

Keywords: aerobic glycolysis, Warburg effect, TGF-beta, epithelial-to-mesenchymal transition, lung epithelial cells, EMT, cancer metastasis, metabolic reprogramming, lactate dehydrogenase, pulmonary fibrosis, cell death discovery, glycolytic flux

RUNX3 belongs to the RUNX family of transcription factors, DNA-binding proteins that orchestrate the expression of large networks of genes by attaching to specific promoter and enhancer sequences. In healthy tissue, RUNX3 is intimately involved in cell differentiation, immune cell development, and the suppression of abnormal growth. In many tumors, however, the gene is silenced through mechanisms such as promoter hypermethylation, in which methyl groups are added to the DNA region controlling RUNX3 expression, effectively switching the gene off without altering its sequence. The loss of RUNX3 function removes a natural brake on cell proliferation, allowing tumor cells to divide unchecked, evade programmed cell death, and acquire invasive properties. The new review emphasizes that this same loss also appears to blunt the sensitivity of cancer cells to chemotherapeutic agents.

The mechanistic breadth of RUNX3’s influence on chemosensitivity is striking. According to the review, RUNX3 modulates at least seven interconnected processes that govern drug response: apoptosis, drug efflux, cell cycle dynamics, oxidative stress, cancer stem cell properties, epithelial-to-mesenchymal transition, and metabolic reprogramming. Each of these represents a well-documented route by which tumors develop resistance to treatment. When RUNX3 is functional, it promotes apoptosis, the controlled self-destruction of damaged cells, by influencing key regulators of the intrinsic death pathway. This means that in RUNX3-proficient tumors, chemotherapy-induced DNA damage is more likely to trigger the cellular suicide program that drugs such as platinum agents and taxanes rely upon to kill malignant cells.

Drug efflux is another arena in which RUNX3 exerts considerable power. Chemotherapy frequently fails because tumor cells overexpress ATP-binding cassette transporters, membrane pumps that expel cytotoxic drugs before they can accumulate to lethal concentrations. The review details evidence that RUNX3 can suppress the expression of these efflux pumps, thereby keeping drug concentrations inside cancer cells high enough to be effective. Conversely, when RUNX3 is lost or silenced, efflux machinery ramps up, and drugs are pumped out almost as quickly as they enter. This single regulatory relationship helps explain why patients with epigenetically silenced RUNX3 often respond poorly to standard regimens, and why restoring RUNX3 expression could resensitize tumors to agents they had previously resisted.

Cell cycle control adds a further layer of complexity. Many chemotherapeutics are most effective against rapidly dividing cells, because they target DNA replication or mitosis. RUNX3 helps enforce checkpoint controls that can either halt division in damaged cells or push them toward death. The review describes how RUNX3 interacts with cyclin-dependent kinase inhibitors and other cell cycle regulators to modulate the pace of proliferation. In tumors where RUNX3 is absent, cells may accumulate in phases of the cell cycle that render them less vulnerable to phase-specific drugs, a phenomenon known as quiescence-associated resistance. Reinstating RUNX3 activity could therefore reposition tumor cells in phases of the cycle where chemotherapy is most lethal.

Perhaps the most clinically provocative section of the review concerns cancer stem cells and epithelial-to-mesenchymal transition. Cancer stem cells are a small subpopulation of tumor cells with the capacity for self-renewal and the ability to seed new tumors. They are notoriously resistant to conventional chemotherapy and are widely believed to be responsible for relapse after seemingly successful treatment. EMT, meanwhile, is the process by which epithelial cancer cells acquire motile, mesenchymal characteristics, enhancing invasion and metastasis while simultaneously increasing drug tolerance. The review marshals evidence that RUNX3 suppresses both programs. By restraining EMT-associated transcription factors and limiting stem-like properties, RUNX3 reduces the pool of drug-tolerant cells within a tumor. Its loss permits the expansion of these resilient populations, setting the stage for treatment failure and disease recurrence.

Metabolic reprogramming and oxidative stress responses round out the mechanistic picture. Cancer cells rewire their metabolism to favor survival under harsh conditions, shifting toward glycolysis, altering mitochondrial function, and mounting robust antioxidant defenses that neutralize the reactive oxygen species generated by many chemotherapeutic drugs. The review indicates that RUNX3 influences these metabolic pathways, potentially tipping the balance back toward drug-induced oxidative damage. In RUNX3-deficient tumors, enhanced antioxidant capacity and metabolic flexibility allow cells to withstand the biochemical assault of treatment. This suggests that combining RUNX3 restoration with standard chemotherapy could amplify the lethal effects of treatment while simultaneously closing off the escape routes tumors typically use to survive.

Beyond its mechanistic roles, the review positions RUNX3 as a candidate biomarker for predicting chemotherapy response. Because RUNX3 silencing is often detectable through methylation assays or expression profiling of tumor biopsies, clinicians could conceivably use RUNX3 status to stratify patients before treatment begins. Those with intact RUNX3 expression might be expected to respond well to standard regimens, while those with silenced RUNX3 could be flagged for intensified therapy, epigenetic priming, or enrollment in trials of RUNX3-targeted interventions. The authors argue that this predictive capacity, combined with the molecule’s mechanistic centrality, makes RUNX3 a promising therapeutic target in its own right. Strategies to modulate RUNX3 include demethylating agents that reactivate the silenced gene, small molecules or gene therapy approaches that boost its expression, and drugs that mimic its downstream effects on apoptosis and efflux pathways.

The therapeutic opportunities are significant but come with caveats that the review acknowledges. RUNX3 is a transcription factor, and transcription factors have historically been considered difficult drug targets because they lack the enzymatic pockets that small-molecule inhibitors typically exploit. Restoring a tumor suppressor, rather than inhibiting an oncogene, also presents unique pharmacological challenges. Nevertheless, advances in epigenetic therapy, targeted gene delivery, and the development of molecules that stabilize or enhance transcription factor complexes are steadily eroding these barriers. The review suggests that combination approaches, in which RUNX3 restoration is paired with conventional chemotherapy or epigenetic drugs, may offer the most realistic near-term path to clinical benefit, resensitizing resistant tumors and extending the useful lifespan of existing drug regimens.

As chemoresistance remains a leading cause of cancer-related mortality worldwide, the identification of actionable regulators like RUNX3 carries substantial clinical weight. The synthesis presented in Cancer Cell International consolidates a decade of scattered findings into a coherent framework, positioning RUNX3 not merely as a passive marker of poor prognosis but as an active, manipulable node in the resistance machinery of tumors. If ongoing and future studies can translate RUNX3 modulation into safe and effective clinical interventions, oncologists may gain a powerful new tool for predicting treatment response and for converting resistant cancers back into treatable ones. For patients facing the devastating diagnosis of chemotherapy-resistant disease, that possibility represents a genuinely hopeful frontier in cancer research.

Subject of Research: The role of the RUNX3 transcription factor in regulating cancer chemoresistance and its potential as a therapeutic target and biomarker

Article Title: The role of RUNX3 in cancer chemoresistance: regulation and therapeutic opportunities

Article References: Gong, Y., Deng, H., Liao, X., & Zhang, J. (2026). The role of RUNX3 in cancer chemoresistance: regulation and therapeutic opportunities. Cancer Cell International. https://doi.org/10.1186/s12935-026-04460-7

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04460-7

Keywords: RUNX3, chemoresistance, cancer, transcription factor, tumor suppressor, apoptosis, drug efflux, epithelial-to-mesenchymal transition, cancer stem cells, metabolic reprogramming, biomarker, therapeutic target

Pancreatic cancer remains notoriously difficult to treat owing to its aggressive nature and late diagnosis. At the heart of this malignancy’s lethal behavior lies a complex network of genetic and epigenetic factors that regulate tumor cell plasticity and dissemination. The identification of BNC2 as a novel oncogenic driver offers a new avenue for therapeutic intervention. By delving into the transcriptional landscape, the researchers demonstrated that BNC2 modulates a gene signature that fosters an environment conducive to cancer cell migration and invasion.

The study employed sophisticated molecular biology techniques, including chromatin immunoprecipitation sequencing (ChIP-seq) and RNA sequencing, to unravel the direct targets of BNC2. Among these targets, COL3A1, encoding type III collagen, surfaced as a critical mediator. Type III collagen, a component of the extracellular matrix (ECM), is known to influence tumor microenvironment dynamics, tissue remodeling, and metastatic potential. The elevation of COL3A1 expression under BNC2 control underscores a mechanistic link between transcription factor activity and ECM modulation in pancreatic cancer progression.

Integral to the process of metastasis is the epithelial-to-mesenchymal transition, whereby epithelial cancer cells acquire mesenchymal traits that confer migratory and invasive properties. The team’s data distinctly showed BNC2’s role in regulating EMT-related gene expression, thereby facilitating the transition and enabling tumor cells to detach and invade surrounding tissues. This regulatory effect positions BNC2 not just as a bystander, but as a master regulator orchestrating phenotypic plasticity in pancreatic cancer.

Further exploration of the molecular pathways revealed that BNC2 influences a network of EMT transcription factors, including pivotal players such as Snail and Twist. The coordinated upregulation of these factors in response to BNC2 activity substantiates a cascade model in which BNC2 drives a transcriptional program conducive to cancer cell dissemination. These insights pave the way for targeting BNC2 or its downstream effectors to disrupt EMT and metastasis.

Importantly, the research team validated their in vitro findings using in vivo pancreatic cancer models. Animal studies fortified the premise that BNC2 overexpression dramatically accelerates tumor growth and metastatic spread, correlating with increased COL3A1 levels and pronounced EMT features. This translational component of the study underscores the clinical relevance of the molecular insights gained and positions BNC2 as a potential biomarker for aggressive disease.

The clinical implications of these findings are profound. By uncovering BNC2’s centrality to pancreatic cancer progression, new therapeutic strategies that inhibit BNC2 function or its transcriptional network could emerge, potentially halting or reversing tumor spread. The feasibility of targeting transcription factors has historically been challenging, yet advances in drug development could soon overcome this barrier.

Furthermore, the elucidation of COL3A1 as a downstream effector engages the stromal compartment of the tumor, suggesting a dual approach that targets both cancer cells and their microenvironment might be efficacious. This approach aligns with contemporary paradigms in oncology recognizing the tumor microenvironment as an active participant in cancer progression.

The study’s findings also invite reevaluation of diagnostic and prognostic tools for pancreatic cancer. Elevated BNC2 and COL3A1 expression levels could serve as biomarkers identifying patients with high metastatic risk, informing personalized treatment decisions and monitoring strategies. This would mark significant progress in managing a cancer type that desperately needs improved early detection measures.

From a broader perspective, the work contributes significantly to the growing body of knowledge on the transcriptional control of EMT, a process not only critical in cancer but also in normal development and wound healing. The identification of BNC2 as a regulatory node enriches the map of EMT modulators and highlights potential cross-talk between developmental pathways and oncogenic processes.

In sum, the work by Li et al. provides a compelling narrative that defines BNC2 as a novel oncogenic driver whose manipulation of COL3A1 and EMT pathways orchestrates the aggressive behavior of pancreatic cancer. The elucidation of these mechanisms opens up fertile ground for future research aimed at translating these molecular insights into therapeutic breakthroughs capable of improving patient survival.

As pancreatic cancer continues to pose formidable challenges in oncology, discoveries such as this underscore the critical role of fundamental molecular research in driving innovation. The elegance of uncovering transcriptional drivers like BNC2 not only deepens our understanding of cancer biology but also sparks hope for effective, targeted treatments in a field desperately in need of new solutions.

Looking ahead, the next steps will likely involve screening for inhibitors of BNC2 and dissecting the broader regulatory networks that interact with it. Coupling these efforts with clinical studies to validate biomarkers could accelerate the path from bench to bedside and potentially transform the therapeutic landscape for pancreatic cancer patients worldwide.

This study exemplifies how meticulous investigation into the molecular underpinnings of cancer can reveal hidden drivers of malignancy and unlock new prospects for combating one of the most lethal human cancers. BNC2’s emergence as a key transcriptional regulator marks a significant milestone in oncology research with promising implications for future clinical applications.

Subject of Research: The role of BNC2 as a transcriptional driver in pancreatic cancer progression through regulation of the extracellular matrix gene COL3A1 and induction of epithelial-to-mesenchymal transition.

Article Title: BNC2 as a novel driver of pancreatic cancer progression through transcriptional regulation of COL3A1 and epithelial-to-mesenchymal transition.

Article References:
Li, X., Yu, T., Yu, Z. et al. BNC2 as a novel driver of pancreatic cancer progression through transcriptional regulation of COL3A1 and epithelial-to-mesenchymal transition. Med Oncol 43, 11 (2026). https://doi.org/10.1007/s12032-025-03139-9

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03139-9